Time-dependent interaction between lopinavir/ritonavir and fexofenadine

Journal of Clinical Pharmacology

Volumn 46, Issue 7, 2006, Pages 758-767

  Van Heeswijk, Rolf P G ^a,b,c,f   Bourbeau, Marc ^c   Campbell, Pearl ^c,d   Seguin, Isabelle ^a   Chauhan, Bobby M ^e   Foster, Brian C ^e   Cameron, D William ^a,c,e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Department of Pharmacy ^*  (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d Department of Radiation Oncology   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f TIBOTEC BVBA   (Belgium)

Author keywords

Fexofenadine; HIV; Lopinavir; P glycoprotein; Protease inhibitors

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PLASMA HALF LIFE; PROTEIN FUNCTION; STOMACH DISCOMFORT; TASTE DISORDER; VOMITING;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; GENOTYPE; HISTAMINE H1 ANTAGONISTS; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PYRIMIDINONES; RITONAVIR; TERFENADINE; TIME FACTORS;

EID: 33745070264     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006288733     Document Type: Article

References (36)

1. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
2. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of protease inhihitors. AIDS. 2000;14:237-242.
3. Phillips EJ, Rachlis AR, Ito S. Digoxin toxicity and ritonavir: a drug interaction mediated through P-glycoprotein? AIDS. 2003;17:1577-1578.
4. Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999;56:383-389.
5. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol. 2002;42:1269-1274.
6. Drewe J, Gutman H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57: 1147-1152.
7. Perloff MD, von Moltke LL, Greenblatt DJ. Ritonavir and dexamethasone induce expression of CYP3A4 and P-glycoprotein in rats. Xenobiotica. 2004;34:133-150.
8. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76:73-84.
9. Penzak SR, Shen JM, Alfaro RM, et al. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit. 2004;26:322-330.
10. Vishnuvardhan D, von Moltke LL, Richtert C, Greenblatt DJ. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003;17:1092-1094.
11. Heeswijk van RPG, Veldkamp AI, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antiviral Ther. 2001;6:201-229.
12. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769-802.
13. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphism of the multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
14. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27:866-871.
15. Molimard M, Diquet B, Strolin Beneditti M. Comparison of pharmacokinetics and metabolism of desloratidine, fexofenadine, levocetirizine and mizolastine in humans. Fund Clin Pharmacol. 2004;18:399-411.
16. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine and its enantiomers in healthy male volunteers. Biopharm Drug Dispos. 1998;19:455-463.
17. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther. 2001;69:114-121.
18. Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2003;73:41-50.
19. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77:17-23.
20. Robbins DK, Castles MA, Pack DJ, Bhargava VO, Weir SJ. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos. 1998;19: 455-463.
21. Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratidine, fexofenadine, levocetirizine and mizolastine in humans. Fund Clin Pharmacol. 2004;18:399-411.
22. Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernas H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin Pharmacol Ther. 2003;74:423-436.
23. Petri N, Tannergren C, Rungstad D, Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004;21:1398-1404.
24. Tayrouz Y, Ganssmann B, Ding R, et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther. 2001;70:405-414.
25. Niemi M, Kivisto KT, Hofmann U, et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SCLO1B1 gene (encoding OATP1B1). Br J Clin Pharm. 2005;59: 602-604.
26. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71:11-20.
27. Gupta A, Zhang Y, Unadkat JD, Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004;310:334-341.
28. Chan S, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004;21:25-51.
29. Drescher S, Schaeffler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002;53:526-534.
30. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
31. Greenblatt DJ, von Moltle LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther. 2000;67:335-341.
32. Perloff MD, von Moltke LL, Marchand JE, Greenblatt DJ. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001;90:1829-1837.
33. Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostatis and drug metabolism. Arch Biochem Biophys. 2005;433:397-412.
34. Dussault I, Lin M, Hollister K, et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001;276:33309-33312.
35. Marzolini C, Tirona RG, Lee W, et al. Unexpected complexity in nuclear receptor activation by HIV protease inhibitors and induction of CYP enzymes and transporters. In: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 135.
36. Gisolf EH, van Heeswijk RP, Hoetelmans RWM, Danner SA. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS. 2000;14:801-805.